Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor

Thomas Jacob Urban, Paola Nicoletti, Naga P. Chalasani, José Serrano, Andrew Stolz, Ann K. Daly, Guruprasad P. Aithal, John Dillon, Victor Navarro, Joseph Odin, Huiman X. Barnhart, David Ostrov, Nanye Long, Elizabeth Trilby Cirulli, Paul Brent Watkins, Robert John Fontana

Research output: Contribution to journalArticle

48 Citations (Scopus)
277 Downloads (Pure)

Abstract

BACKGROUND & AIMS: Minocycline hepatotoxicity can present with prominent autoimmune features in previously healthy individuals. The aim of this study was to identify genetic determinants of minocycline DILI in a well-phenotyped cohort of patients.

METHODS: Caucasian patients with minocycline DILI underwent genome-wide genotyping and were compared to unexposed population controls. Human leukocyte antigen (HLA) binding of minocycline was assessed using AutoDock Vina.

RESULTS: Amongst the 25 cases, 80% were female, median age was 19 years and median latency from drug start to DILI onset was 318 days. At presentation, 76% had acute hepatocellular liver injury, median ALT 1077 U/L (range: 63 to 2333), median bilirubin 4.5 mg/dl (range: 0.2 to 16.7), and 90% had a +ANA. During follow-up, 50% were treated with corticosteroids and no subjects died or required a liver transplant. A significant association was noted between HLA-B∗35:02 and risk for minocycline-DILI; a 16% carrier frequency in DILI cases compared to 0.6% in population controls (Odds Ratio: 29.6, 95% CI: 7.8-89.8, p=2.5 x 10(-8)). Verification of HLA-B∗35:02 imputation was confirmed by sequence-based HLA typing. HLA-B∗35:02 carriers had similar presenting features and outcomes compared to non-carriers. In silico modeling studies support the hypothesis that direct binding of minocycline to this novel HLA risk allele might be an important initiating event in minocycline-DILI.

CONCLUSION: HLA-B∗35:02 is a rare HLA allele that was more frequently identified in the 25 minocycline-DILI cases compared to population controls. If confirmed in other cohorts, this HLA allele may prove to be a useful diagnostic marker of minocycline DILI.

Original languageEnglish
Pages (from-to)137-144
Number of pages8
JournalJournal of Hepatology
Volume67
Issue number1
Early online date18 Mar 2017
DOIs
Publication statusPublished - Jul 2017

Keywords

  • Autoimmunity
  • Drug-induced liver injury
  • Genetic association
  • Human leukocyte antigen
  • Single nucleotide polymorphism

Fingerprint Dive into the research topics of 'Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor'. Together they form a unique fingerprint.

  • Profiles

    No photo of John Dillon

    Dillon, John

    Person: Academic

    Cite this

    Urban, T. J., Nicoletti, P., Chalasani, N. P., Serrano, J., Stolz, A., Daly, A. K., Aithal, G. P., Dillon, J., Navarro, V., Odin, J., Barnhart, H. X., Ostrov, D., Long, N., Cirulli, E. T., Watkins, P. B., & Fontana, R. J. (2017). Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. Journal of Hepatology, 67(1), 137-144. https://doi.org/10.1016/j.jhep.2017.03.010